ADC Therapeutics S.A.
ADCT · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $2 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | -$0 | $0 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 1.8% | -66.9% | 518.9% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 91.6% | 96.4% | 98.4% | 95.9% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -144.9% | -209.6% | -51.3% | -679.7% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -222.8% | -345.1% | -74.9% | -678.2% |
| EPS Diluted | -1.62 | -2.94 | -1.99 | -3 |
| % Growth | 44.9% | -47.7% | 33.7% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |